Photo via Wikimedia Commons
Advertisement
Advertisement
That’s not to say that the Supreme Court ruling isn’t going to shake things up in the biotech industry. In the realm of diagnostics, the ruling is likely to promote more competition for genetic testing, breaking up the monopolies that companies like Myriad had over testing for genetic mutations, and, theoretically at least, lead to more competitive pricing for these types of tests."They drew a line in the sand between genomic and cDNA. Industries will adapt fairly rapidly."
Advertisement
Advertisement